<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119106</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHSTP-4370</org_study_id>
    <nct_id>NCT00119106</nct_id>
  </id_info>
  <brief_title>Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand</brief_title>
  <official_title>Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bangkok Metropolitan Administration Medical College and Vajira Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goals of this study are to assess the safety and efficacy of daily tenofovir to&#xD;
      prevent parenteral HIV infection among injection drug users (IDUs). Assessment of changes in&#xD;
      HIV associated risk behaviors, adherence to study drug, and, among IDU who become&#xD;
      HIV-infected during the trial, evaluation of HIV viral load set point, CD4 counts, genetic&#xD;
      characterization of infecting HIV viruses, and antiretroviral resistance will also be done.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II/III, randomized, double-blind, placebo-controlled study of the safety and&#xD;
      efficacy of chemoprophylactic tenofovir, administered orally once daily to IDUs. The study&#xD;
      will be conducted in Bangkok at 17 BMA Drug Treatment Clinics. Study participants will be&#xD;
      randomized (1:1) to receive tenofovir 300 mg or placebo. Participants will be evaluated for&#xD;
      adverse events and HIV seroconversion.&#xD;
&#xD;
      Primary endpoints: The primary efficacy endpoint will be measured by rates of HIV&#xD;
      seroconversion measured at monthly intervals. The primary safety endpoints will be measured&#xD;
      by the frequency of Grade 3 or 4 renal or hepatic function laboratory toxicities or clinical&#xD;
      toxicities in blinded tenofovir and placebo arms, as defined by the Gilead-modified NIAID&#xD;
      Adult Common Toxicity Tables, and which cannot be directly attributed to a cause other than&#xD;
      study medications; and the frequency of adverse clinical events in tenofovir and placebo&#xD;
      arms.&#xD;
&#xD;
      Secondary endpoints: Changes in HIV associated risk behaviors will be measured by rates of&#xD;
      reported injection drug use and injection drug use frequency during the trial; rates of&#xD;
      reported needle sharing; the number of unprotected sexual acts over the course of the trial;&#xD;
      number of reported sexual partners over the course of the trial; and proportional use of&#xD;
      condoms during sexual intercourse.&#xD;
&#xD;
      Medication adherence will be measured as: rates, by interview and documentation on tenofovir&#xD;
      adherence card, of participants taking at least six (86%) of seven daily doses of study drug&#xD;
      each of the four weeks preceding the monthly study visit. Differences in virologic and&#xD;
      immunologic responses to HIV infection among tenofovir and placebo recipients will be&#xD;
      measured by: plasma viral load, measured by quantitative RNA PCR, a predictor of clinical&#xD;
      progression of HIV disease; 14 CD4 cell counts will be measured by flow cytometry. Rates and&#xD;
      nature of HIV antiretroviral genotypic and phenotypic resistance will be measured. Genetic&#xD;
      characteristics of infecting HIV viruses including DNA sequence analysis and antibody binding&#xD;
      studies will be conducted.&#xD;
&#xD;
      In phase II, participants will be followed months 0, 1, 2, 3, then 3 monthly with hematology&#xD;
      and chemistry tests and laboratory evaluations of renal and hepatic function until 200&#xD;
      person-years of observation are accrued. At that point, a DSMB safety assessment will be&#xD;
      conducted. Follow-up of enrolled participants will continue during the DSMB safety&#xD;
      assessment. If safety is confirmed, all phase II participants will continue, and additional&#xD;
      participants will be enrolled into the phase III portion of the trial. Accrual of the target&#xD;
      enrollment of 2,400 IDUs is anticipated to take 48 months.&#xD;
&#xD;
      Participants will choose between two follow-up schedules: monthly (every 4 weeks) or monthly&#xD;
      plus daily with directly observed therapy (DOT). During DOT visits clinic staff will witness&#xD;
      the participant swallow his/her study medication and clinic staff will initial the&#xD;
      participant's tenofovir adherence card. Monthly visits will be the same for both groups and&#xD;
      will include an assessment of tenofovir adherence and adverse events, a pill count and&#xD;
      collection of unused pills, provision of a new 1 month supply of study medication, pre- and&#xD;
      post-test HIV counseling, rapid oral HIV testing, urine pregnancy test (for female&#xD;
      participants), HIV risk reduction counseling, and medication adherence counseling. At 3, 6,&#xD;
      and every 3 months thereafter monthly procedures will be supplemented with a risk behavior&#xD;
      questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of HIV Seroconversion</measure>
    <time_frame>From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years</time_frame>
    <description>Kaplan Meier survival curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Toxicity</measure>
    <time_frame>Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years</time_frame>
    <description>Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 6.9 years</time_frame>
    <description>Number of Participants with adverse clinical events in tenofovir and placebo arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Injecting and Sharing Needles</measure>
    <time_frame>Participants were asked about injecting and needle sharing behaviors at enrollment and every 3 month visit, up to 6.9 years</time_frame>
    <description>Number of Participants reporting injecting and sharing needles:&#xD;
Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Study Drug/Placebo</measure>
    <time_frame>Participants were asked about adherence at 3 month visits, up to 6.9 years.</time_frame>
    <description>Mean number of days that participants took study drug based on study drug diaries by study group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group</measure>
    <time_frame>Among people who seroconverted, viral load was measured at month 1, 2, and every 4 months after HIV seroconversion</time_frame>
    <description>Plasma HIV RNA concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Participants Who Reported More Than One Sexual Partner at Baseline</measure>
    <time_frame>At enrolment</time_frame>
    <description>Number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tenofovir-associated Resistance Mutations.</measure>
    <time_frame>Specimens collected at the time of HIV seroconversion</time_frame>
    <description>Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2413</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>tenofovir disoproxil fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Tenofovir arm will receive daily oral tenofovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in the Placebo are will receive daily oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Antiretroviral</description>
    <arm_group_label>tenofovir disoproxil fumarate</arm_group_label>
    <other_name>Tenofovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Report injection drug use in the 6 months before screening&#xD;
&#xD;
          -  Possess a Thai National Identification Card&#xD;
&#xD;
          -  Laboratory values as follows within 2 weeks before enrollment:&#xD;
&#xD;
          -  HIV oral fluid test non-reactive at screening and pre-enrollment visits&#xD;
&#xD;
          -  Hemoglobin 9 gm/dL&#xD;
&#xD;
          -  ALT and AST 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin 1.5 mg/dL&#xD;
&#xD;
          -  Serum amylase 1.5 x ULN&#xD;
&#xD;
          -  Serum phosphorus 2.2 mg/dL&#xD;
&#xD;
          -  No evidence of current or chronic Hepatitis B infection by serology&#xD;
&#xD;
          -  Calculated creatinine clearance 60 mL/min by the Cockcroft-Gault formula where&#xD;
             creatinine clearance in mL/min = Male: (140 - age in years) x (wt in kg)/72 x (serum&#xD;
             creatinine in mg/dL) Female:(140 - age in years) x (wt in kg) x 0.85/72 x (serum&#xD;
             creatinine in mg/dL)&#xD;
&#xD;
          -  Willing to abstain from sexual intercourse or use effective contraception during the&#xD;
             trial (oral, injection, or barrier), for women&#xD;
&#xD;
          -  Willing and able to provide informed consent for study participation&#xD;
&#xD;
          -  Available and committed to DOT or monthly follow-up for at least 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinic physicians will determine if a subject with chronic illness requiring&#xD;
             prescription medication can not enroll (medication used for drug treatment is allowed)&#xD;
&#xD;
          -  Positive urine pregnancy test&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  History of significant renal, liver, or bone disease&#xD;
&#xD;
          -  Any other clinical condition or prior therapy that, in the opinion of the clinic&#xD;
             physician, would make the subject unsuitable for the study or unable to comply with&#xD;
             the dosing requirements&#xD;
&#xD;
          -  Concurrent participation in any other HIV prevention trial or drug/vaccine safety&#xD;
             trial. AIDSVAX B/E HIV vaccine trial (CDC protocol #2076) participants and Extension&#xD;
             Study (CDC protocol #3750) participants may be screened for enrollment in the Bangkok&#xD;
             Tenofovir Study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kachit Choopanya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangkok Tenofovir Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael T Martin, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn Paxton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thailand Ministry of Public Health - U.S. CDC Collaboration</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013 Jun 15;381(9883):2083-90. doi: 10.1016/S0140-6736(13)61127-7. Epub 2013 Jun 13.</citation>
    <PMID>23769234</PMID>
  </reference>
  <reference>
    <citation>Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Chaipung B, Worrajittanon D, Leethochawalit M, Chiamwongpaet S, Kittimunkong S, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Holtz TH, Samandari T, Choopanya K; Bangkok Tenofovir Study Group. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study. Lancet HIV. 2017 Feb;4(2):e59-e66. doi: 10.1016/S2352-3018(16)30207-7. Epub 2016 Nov 18.</citation>
    <PMID>27866873</PMID>
  </reference>
  <reference>
    <citation>Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Curlin ME, Na-Pompet S, Warapronmongkholkul A, Kittimunkong S, Gvetadze RJ, McNicholl JM, Paxton LA, Choopanya K; Bangkok Tenofovir Study Group. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS. 2015 Apr 24;29(7):819-24. doi: 10.1097/QAD.0000000000000613.</citation>
    <PMID>25985403</PMID>
  </reference>
  <reference>
    <citation>Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Gvetadze RJ, Kittimunkong S, Curlin ME, Worrajittanon D, McNicholl JM, Paxton LA, Choopanya K; Bangkok Tenofovir Study Group. Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs. PLoS One. 2014 Mar 25;9(3):e92809. doi: 10.1371/journal.pone.0092809. eCollection 2014.</citation>
    <PMID>24667938</PMID>
  </reference>
  <reference>
    <citation>Vanichseni S, Martin M, Suntharasamai P, Sangkum U, Mock PA, Gvetadze RJ, Curlin ME, Leethochawalit M, Chiamwongpaet S, Chaipung B, McNicholl JM, Paxton LA, Kittimunkong S, Choopanya K. High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012. Am J Public Health. 2015 Jun;105(6):1136-41. doi: 10.2105/AJPH.2014.302473. Epub 2015 Apr 16.</citation>
    <PMID>25880964</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <results_first_submitted>July 28, 2015</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2021</results_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Prevention</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Concept sheets are reviewed and approved, modified, or declined by research team.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data available after 2014</ipd_time_frame>
    <ipd_access_criteria>Concept sheets are reviewed and approved, modified, or declined by research team.</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir</title>
          <description>Tenofovir&#xD;
Tenofovir</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Tenofovir</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1204"/>
                <participants group_id="P2" count="1209">2 participants later found to be HIV infected at baseline. Therefore 1207 in mITT analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1025"/>
                <participants group_id="P2" count="1031"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>HIV infected at baseline</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir</title>
          <description>Tenofovir&#xD;
Tenofovir</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Tenofovir</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1204"/>
            <count group_id="B2" value="1207"/>
            <count group_id="B3" value="2411"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="8"/>
                    <measurement group_id="B2" value="31" spread="8"/>
                    <measurement group_id="B3" value="31" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="487"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="958"/>
                    <measurement group_id="B2" value="966"/>
                    <measurement group_id="B3" value="1924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1204"/>
                    <measurement group_id="B2" value="1207"/>
                    <measurement group_id="B3" value="2411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rates of HIV Seroconversion</title>
        <description>Kaplan Meier survival curve.</description>
        <time_frame>From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Rates of HIV Seroconversion</title>
          <description>Kaplan Meier survival curve.</description>
          <units>Infections/ 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1204"/>
                <count group_id="O2" value="1209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Toxicity</title>
        <description>Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities</description>
        <time_frame>Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years</time_frame>
        <population>creatinine clearance measured in all participants every 3 months</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir</title>
            <description>Tenofovir&#xD;
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Toxicity</title>
          <description>Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities</description>
          <population>creatinine clearance measured in all participants every 3 months</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1204"/>
                <count group_id="O2" value="1209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Number of Participants with adverse clinical events in tenofovir and placebo arms</description>
        <time_frame>Up to 6.9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir</title>
            <description>Tenofovir&#xD;
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of Participants with adverse clinical events in tenofovir and placebo arms</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1204"/>
                <count group_id="O2" value="1209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1098"/>
                    <measurement group_id="O2" value="1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Injecting and Sharing Needles</title>
        <description>Number of Participants reporting injecting and sharing needles:&#xD;
Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing.</description>
        <time_frame>Participants were asked about injecting and needle sharing behaviors at enrollment and every 3 month visit, up to 6.9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir</title>
            <description>Tenofovir&#xD;
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Injecting and Sharing Needles</title>
          <description>Number of Participants reporting injecting and sharing needles:&#xD;
Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1204"/>
                <count group_id="O2" value="1207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Study Drug/Placebo</title>
        <description>Mean number of days that participants took study drug based on study drug diaries by study group.</description>
        <time_frame>Participants were asked about adherence at 3 month visits, up to 6.9 years.</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir</title>
            <description>Tenofovir&#xD;
Tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Study Drug/Placebo</title>
          <description>Mean number of days that participants took study drug based on study drug diaries by study group.</description>
          <population>All participants</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1204"/>
                <count group_id="O2" value="1207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="23"/>
                    <measurement group_id="O2" value="84" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group</title>
        <description>Plasma HIV RNA concentrations.</description>
        <time_frame>Among people who seroconverted, viral load was measured at month 1, 2, and every 4 months after HIV seroconversion</time_frame>
        <population>Participants who seroconverted during follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir</title>
            <description>Received tenofovir</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group</title>
          <description>Plasma HIV RNA concentrations.</description>
          <population>Participants who seroconverted during follow-up.</population>
          <units>Copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="929829" spread="2272690"/>
                    <measurement group_id="O2" value="120061" spread="222612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Participants Who Reported More Than One Sexual Partner at Baseline</title>
        <description>Number of participants</description>
        <time_frame>At enrolment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Group</title>
            <description>Tenofovir participants</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo recipients</description>
          </group>
        </group_list>
        <measure>
          <title>Number Participants Who Reported More Than One Sexual Partner at Baseline</title>
          <description>Number of participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1204"/>
                <count group_id="O2" value="1209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tenofovir-associated Resistance Mutations.</title>
        <description>Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups.</description>
        <time_frame>Specimens collected at the time of HIV seroconversion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir</title>
            <description>Participants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tenofovir-associated Resistance Mutations.</title>
          <description>Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were assessed for adverse events from the date the participant enrolled and started study drug until the participant completed follow-up, a maximum of 6.9 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir</title>
          <description>Tenofovir&#xD;
Tenofovir</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Tenofovir</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1204"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1209"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="1204"/>
                <counts group_id="E2" subjects_affected="246" subjects_at_risk="1209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Any serious adverse event</sub_title>
                <counts group_id="E1" events="340" subjects_affected="227" subjects_at_risk="1204"/>
                <counts group_id="E2" events="375" subjects_affected="246" subjects_at_risk="1209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ICD-10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1098" subjects_at_risk="1204"/>
                <counts group_id="E2" subjects_affected="1083" subjects_at_risk="1209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AE</sub_title>
                <description>Other adverse events</description>
                <counts group_id="E1" events="10965" subjects_affected="1098" subjects_at_risk="1204"/>
                <counts group_id="E2" events="11550" subjects_affected="1083" subjects_at_risk="1209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal toxicity</sub_title>
                <description>NIH Grade 3 or 4</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1204"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Participants could have under-reported stigmatised behaviours such as injecting drugs.30</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Martin</name_or_title>
      <organization>CDC</organization>
      <phone>662 580 0669</phone>
      <email>ZND9@CDC.GOV</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

